| Name | HMW MAA |
|---|---|
| Synonyms | CSPG 4; NG2; MCSP; MSK16; CSPG4; Chondroitin sulfate proteoglycan 4; Chondroitin sulfate proteoglycan 4 precursor; Chondroitin sulfate proteoglycan NG2… |
| Name | MAA |
|---|---|
| CAS | methylarsonic acid |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 8368768 | Chen ZJ, Ferrone S: Comparison of the binding parameters to melanoma cells of antihuman high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies (mAb) and syngeneic anti-anti-idiotypic (anti-anti-id) mAb. Ann N Y Acad Sci. 1993 Aug 12;690:398-401. |
1(0,0,0,1) | Details |
| 20309546 | Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P: Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother. 2010 Mar 23. Melanoma chondroitin sulfate proteoglycan (MCSP; also called CSPG4, NG2, HMW-MAA, MSK16, MCSPG, MEL-CSPG, or gp240) is a surface antigen frequently expressed on human melanoma cells, which is involved in cell adhesion, invasion and spreading, angiogenesis, complement inhibition, and signaling. |
1(0,0,0,1) | Details |
| 1409414 | Kageshita T, Yamada M, Arao T, Ferrone S: Expression of high molecular weight-melanoma associated antigen (HMW-MAA) in primary ALM lesions is associated with a poor prognosis. Pigment Cell Res. 1992;Suppl 2:132-5. |
1(0,0,0,1) | Details |
| 15650259 | Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S: Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann N Y Acad Sci. 2004 Dec;1028:340-50. These findings parallel the inhibition of the rat homologue of HMW-MAA NG2 function by anti-NG2 antibodies. |
1(0,0,0,1) | Details |
| 15373771 | Mittelman A, Tiwari R, Lucchese G, Willers J, Dummer R, Kanduc D: Identification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining. J Invest Dermatol. 2004 Oct;123(4):670-5. |
1(0,0,0,1) | Details |
| 16470181 | Ulmer A, Fierlbeck G: Circulating tumor cells and detection of the melanoma-associated antigen HMW-MAA in the serum of melanoma patients. J Invest Dermatol. 2006 Apr;126(4):914-5; author reply 915-6. |
1(0,0,0,1) | Details |
| 19690617 | Selbo PK, Rosenblum MG, Cheung LH, Zhang W, Berg K: Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel. PLoS One. 2009 Aug 19;4(8):e6691. METHODOLOGY AND PRINCIPAL FINDINGS: The recombinant single-chain fusion construct scFvMEL/rGel is composed of an antibody targeting the progenitor marker HMW-MAA/NG2/MGP/gp240 and the highly effective toxin gelonin (rGel). |
1(0,0,0,1) | Details |
| 3920101 | Matsui M, Nakanishi T, Noguchi T, Imai K, Yachi A, Ferrone S: Suppression of human melanoma growth in nude mice injected with anti high-molecular-weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin. Jpn J Cancer Res. 1985 Feb;76(2):119-23. The cytotoxic agent purothionin purified from barley was covalently conjugated to the anti-human high-molecular-weight melanoma-associated antigen (HMW-MAA) monoclonal antibody (MoAb) 225.28S by utilizing water-soluble carbodiimide. |
1(0,0,0,1) | Details |
| 3243979 | Castello G, Mansi L, Leonardi E, Lastoria S, Melillo G: Short-term effects of i.v. injected murine 99MTc-F (ab') 2 fragments of an anti-melanoma antibody (HMW-MAA 225.28 S) on haemato-immunological parameters in patients with melanoma. Int J Biol Markers. 1988 Apr-Jun;3(2):140-4. |
2(0,0,0,2) | Details |
| 8227707 | Ferrone S, Kageshita T, Hirai S: Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies. J Dermatol. 1993 Sep;20(9):533-9. In this study, we have utilized the human high molecular weight-melanoma associated antigen (HMW-MAA) as a target for active specific immunotherapy with mouse anti-idiotypic (anti-id) monoclonal antibodies (mAb) in patients with malignant melanoma. |
2(0,0,0,2) | Details |
| 1603113 | Mittelman A, Puccio C, Chun H, Ahmed T: Humoral antimelanoma immunity: induction by mouse antiidiotypic mAb, MK2-23 and association with survival of patients with advanced melanoma. Mt Sinai J Med. 1992 May;59(3):234-7. This study has shown that a mouse antiidiotypic mAb bearing a mirror image of HMW-MAA can break tolerance to a well-defined self HMW-MAA and can induce humoral anti HMW-MAA immunity in patients with melanoma. |
2(0,0,0,2) | Details |
| 18829565 | Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y: Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008 Oct 1;68(19):8066-75. The high molecular weight melanoma-associated antigen (HMW-MAA), also known as melanoma chondroitin sulfate proteoglycan, has been used as a target for the immunotherapy of melanoma. |
1(0,0,0,1) | Details |
| 15252841 | Dummer R, Mittelman A, Fanizzi FP, Lucchese G, Willers J, Kanduc D: Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int J Cancer. 2004 Sep 20;111(5):720-6. |
2(0,0,0,2) | Details |
| 1409413 | Chen ZJ, Yang H, Liu CC, Mittelman A, Ferrone S: Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma. Pigment Cell Res. 1992;Suppl 2:113-22. |
1(0,0,0,1) | Details |
| 9622083 | Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S: Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res. 1998 Jun 1;58(11):2417-25. Furthermore, like some mouse mAbs, human scFvs react with rat neural cells expressing the chondroitin sulfate proteoglycan NG2, which shows 81% homology to the HMW-MAA. |
1(0,0,0,1) | Details |
| 15588226 | Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S: Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004;24(4):267-96. Because of its expression in a large percentage of melanoma lesions and its restricted distribution in normal tissues, the high molecular weight-melanoma-associated antigen (HMW-MAA), also known as the melanoma chondroitin sulfate proteoglycan (MCSP), has been used to implement immunotherapy of melanoma. |
1(0,0,0,1) | Details |